The aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (BPH). Five sets of patients who need a surgical procedure because of low tract urinary symptoms are randomly attributed to one of five sets of treatment: 0, 7, 14, 21 or 28 days of finasteride treatment before the day of the procedure. Prostate histological fragments are conditioned for molecular and histologic studies.
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Drug: finasteride
Clinical Trial Outcome Measures
- Date of the maximum apoptosis in the prostate tissues treated by finasteride
- Molecular mechanisms involved in BPH finasteride induced apoptosis
- Decrease in the frequency of the hemorrhagic incidents after the surgical procedure in patients with a treatment using finasteride
Participating in This Clinical Trial
- Patients with low tract urinary symptoms needing a surgical procedure – No previous treatment with finasteride – No androgen deficiency; no prostate cancer suspected.
Gender Eligibility: Male
Minimum Age: 40 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Hospices Civils de Lyon
- Overall Official(s)
- Alain RUFFION, MD, Principal Investigator, Hospices Civils de Lyon
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.